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Fig. 1. Schematic drawing of operation. See text for 
details. 
in which the dead space around the long elephant trunk 
was filled with clot and further operation was not needed. 2 
The authors highlighted this phenomenon as a further 
potential use of this technique. Crawford and associates 3 
reported complications of this method: kinking and occlu- 
sion of the graft, paraplegia s a result of clot around the 
graft, and peripheral thromboembolism caused by flap- 
ping action. They stated that these complications were 
more likely when the trunk was longer. 
To avoid these potential complications of a long ele- 
phant trunk graft, we used a stent at the distal end to fix 
the graft to the native aortic wall. By this method, we 
could prevent any kinking and flapping action of the graft. 
In addition, we can expect complete obliteration of the 
dead space around the graft even if there are patent 
intercostal rteries, because the hemodynamic conditions 
Fig. 2. Angiograms before (left) and after (right) opera- 
tion. Arrowheads indicate the location of the stent. 
around the graft are similar to those after thromboexclu- 
sion. Although there may be a limitation on indications 
for our method, it is a useful alternative for patients at 
poor risk and those with pulmonary disease. 
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CARDIOPULMONARY BYPASS FOR HEPARIN-INDUCED THROMBOCYTOPENIA: MANAGEMENT 
WITH A HEPARIN-BONDED CIRCUIT AND ENOXAPARIN 
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Heparin-induced thrombocytopenia (HIT) is a poten- 
tially dangerous condition in patients needing cardiac 
operation because the use of unfractionated, standard 
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heparin for cardiopulmonary b pass (CPB) can cause 
severe bleeding, thromboembolism, and even death. Sev- 
eral strategies that avoid or modify the use of standard 
heparin have been tried in such situations but none has 
gained universal acceptance. We describe here the suc- 
cessful use of a heparin-bonded CPB circuit and enoxapa- 
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rin, a low molecular weight heparin (LMWH), in a patient 
with HIT undergoing coronary artery bypass grafting. 
Cas e report. A 70-year-old man with severe triple-vessel 
disease, unstable angina, and severe congestive heart failure 
was referred to us for coronary artery bypass grafting. At the 
previous hospital, HIT was suspected when the platelet 
count dropped from 313 × 109/L to 77 × 109/L after 6 days 
of heparin therapy and confirmed with positive platelet 
aggregation studies with standard heparin. Heparin admin- 
istration was stopped immediately and the patient was given 
therapy with the LMWH enoxaparin (Lovenox, Rhone- 
Poulenc Rorer Pharmaceuticals, Collegeville, Pa.) 30 mg 
every 12 hours, although separate aggregation tests were not 
done with this drug. The platelet count at hospital admission 
was 68 × 109/L and varied from 92 × 109/L to 172 × 109/L 
over the next 4 days. Other coagulation parameters were 
within normal imits. 
CPB was planned with a circuit coated with Carmeda 
Bioactive Surface (Medtronic, Anaheim, Calif.). The cir- 
cuit included a Bio-Medicus vortex pump, a Maxima Plus 
membrane oxygenator, an MVR 1600 venous reservoir 
bag, an arterial ine filter, and a cardiotomy reservoir, all 
manufactured by Medtronic; two 32F caval cannulas and 
an 8.0 aortic cannula (Sarns Inc., Ann Arbor, Mich.) and 
a 14F Argyle aortic root vent (Sherwood Medical, St. 
Louis, Mo.). For added anticoagulation i traoperatively, 
enoxaparin administration was continued using the man- 
ufacturer's recommended protocol. Twenty milligrams of 
enoxaparin was added to the prime, a further 80 mg/m 2
was given after sternotomy, and an infusion was main- 
tained at a rate of 40 mg/m 2 per hour once CPB was 
instituted. Flow rates varied from 2 to 5 L/rain, and 
intermittent ischemic flbrillatory arrest with mild hypo- 
thermia to 34°C was usedl Activated clotting time was 
determined every 30 minutes with a Hemostasis Manage- 
ment Systems device (Medtronic) and ranged from 236 to 
321 seconds. After about 4 hours of CPB, 130 minutes of 
total ischemic time, and completion of six vein grafts, the 
patien t was removed from bypass with intraaortic balloon 
pump support. 
For reversal of heparin, 500 mg of protamine sulphate 
was given. No evidence of visible thrombus, debris, or 
fibrin strands was found on close examination of  the 
bypass circuit. The platelet counts remained higher than 
98 × 109/L throughout the operation. In the first 24 hours 
after operation, the patient lost 1.45 L of fluid, for which 
transfusions of platelets, fresh frozen plasma, and blood 
were given, after which the bleeding settled. Subsequent 
recovery was uneventful. 
Discussion. Whereas ome drop in platelet count is often 
seen after routine use of standard heparin, HIT is a more 
serious problem that occurs in about 3% of patients who 
receive the drug. 1 It is Characterized by thrombocytopenia, 
sometimes thrombosis, and the presence of an immunoglob- 
ulin G antibody causing complemen t C3-mediated platelet 
injury on exposure to standard heparin. Seen more often 
with bovine heparin than with other types, HIT typically 
occurs 7 to 10 days after the start of therapy. Decreasing 
serial platelet counts and laboratory platelet aggregation 
studies and serotonin release assays lead to the diagnosis. 
Treatment includes topping heparin administration, giving 
platelet antiaggregation drugs, and, if needed, substituting 
other anticoagulants for heparin. 
Kondo and associates 2 have reviewed several options for 
cardiac operations in patients with HIT. These include 
deferring operation for a few weeks until the circulating 
platelet antibody levels come down; use of drugs such as 
aspirin, dipyridamole, and iloprost for modifying platelet 
activation in the presence of standard heparin; and using 
fibrinolytic agents and thrombin inhibitors uch as ancrod, 
Hirudin, and Argatroban for anticoagulation. Substitution of 
standard heparin with heparinoids such as heparin sulphate 
and dermatan sulphate and LMWHs such as dalteparin 
(Fragmin), tedelaparin, and enoxaparin has also been re- 
ported.S. 3 LMWHs are fragments cleaved from standard 
heparin that act mainly against clotting factor Xa and 
compared with standard heparin produce less bleeding for 
equivalent antithrombotic effect. Because crossreactivity 
with heparin is known, platelet aggregation tests are recom- 
mended to select he most appropriate LMWH. 3 We used 
enoxaparin because it was readily available and with it the 
platelet counts in our patient remained stable. 
A major drawback of use of LMWHs is the need for 
frequent factor Xa assays for accurate monitoring of 
anticoagulation, which necessitates a specialized setup. 
However, a direct correlation between activated clotting 
time measurements and anti-factor Xa activity has been 
shown, and effective anticoagulation with LMWHs can be 
achieved at activated clotting time values lower than those 
usual for CPB with standard heparin. 4 Another problem 
with LMWHs is the inability to achieve complete reversal 
of antic0agulation at the end of CPB. Protamine only 
neutralizes their anti-IIa action, and the anti-Xa activity 
persists for longer. This may have partly contributed to the 
increased chest tube drainage in our patient. 
A thromboresistant heparin-bonded perfusion circuit 
with its ability to eliminate the need for systemic 
heparinization during CPB 5 is an attractive option in 
cases of HIT. Of particular advantag e with this is a 
circuit with covalently bonded endpoint-attached hep- 
arin (Carmeda) that prevents leaching of any heparin 
into blood. An added benefit of this circuit in patients 
with HIT could be the decreased complement activa- 
tion (C3a and c5a) and hence less contribution to the 
cause of HIT. However, a major limitation of these 
circuits is that the anticoagulant effect is flow depen- 
dent and clotting may be induced at low or stagnant 
flow rates and additional anticoagulation may be re- 
quired for safety. We combined the Carmeda circuit 
with enoxaparin and obtained satisfactory anticoagula- 
tion even at low activated clotting time levels. 
Thus in patients with HIT, cardiac operations can be 
safely done with use of a Carmeda circuit with an appro- 
priate LMWH such as enoxaparin, although further expe- 
rience is needed to establish protocols for monitoring, 
dosing, and neutralization of LMWHs. 
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REOPERATION FOR ANEURYSMAL DISEASE OF THE ASCENDING AORTA IN PATIENTS WITH 
CONCOMITANT AORTIC VALVE INCOMPETENCE 
Matthias Karck, MD, a Joachim Cremer, MD, a Jfirgen Wawersik, MD, b and Axel Haverich, MD, a Kiel, Germany 
An incompetent aortic valve in the presence of recur- 
rent pathologic processes of the ascending aorta poses 
challenges during surgical reentry of the mediastinum. 
This is particularly true of patients who have undergone 
previous cardiac or aortic operations in which the pericar- 
dium was left open with an ascending aortic aneurysm 
encroaching on the sternum. Our experience with seven 
consecutive successful reoperations on patients with such 
combined lesions is described. 
The patient cohort consisted of seven consecutive pa- 
tients operated on between October 1993 and February 
1995. In all patients except one, the femoral artery and 
vein were exposed by groin incision. In two patients the 
sternum was reopened with an oscillating saw without he 
previous institution of femoro-femoral bypass. Retroster- 
nal adhesions were then carefully dissected to make 
feasible the institution of cardiopulmonary bypass by 
means of ascending aortic and right atrial cannulation. In 
five patients, cardiopulmonary bypass was commenced 
through groin cannulation and the systemic temperature 
was lowered slightly. In two instances, complete median 
resternotomy was then performed with an oscillating saw. 
In both of these cases, subsequent dissection of retroster- 
nal adhesions was possible without major bleeding. The 
aorta was then mobilized to enable aortic crossclamping. 
After aortotomy, the procedures were completed accord- 
ing to standard techniques. 
In a subgroup of three patients, however, only the lower 
third of the sternal bone was reopened uring femoro- 
femoral cardiopulmonary b pass. With the sternal edges 
kept carefully elevated, the diaphragmatic aspects of the 
left and right ventricle were dissected first, and all retro- 
sternal adhesions were left untouched. Then both the 
lateral wall of the left ventricle and the apex were exposed 
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to such an extent that the apex could be punctured for 
placement of a vent catheter. In the event of ventricular 
fibrillation, the heart was decompressed manually to avoid 
ventricular overdistention, which could well occur despite 
left ventricular venting. Core cooling was continued to 
achieve a rectal temperature of 25 ° C before induction of 
circulatory arrest. The systemic blood was drained, lead i 
ing to partial collapse of both the heart and the ascending 
aorta. 
Resternotomy and dissection of the remaining retro- 
sternal adhesions were completed, safely and without 
damage to the adjacent right ventricle, pulmonary artery, 
or ascending aorta. The aorta was then mobilized as far 
downstream as was possible without compromising the 
brachiocephalic trunk. At this point, an aortic occluding 
clamp was gently applied and cardiopulmonary b pass was 
reinstituted. The time required to complete dissection of 
retrosternal dhesions during circulatory arrest was less 
than 12 minutes in all cases. In this subgroup of three 
patients, the body of the aneurysm was then incised 
anteriorly and longitudinally. In one patient, ascending 
aortic pathologic processes, including a chronic type A 
dissection with rupture of the false channel into the  
pleural space and additional paravalvular leakage of the 
previously implanted mechanical aortic valve, were seen. 
The other two patients had typical intimal tears in the 
ascending aorta as a result of acute type A aortic dissec- 
tion, with a significant paravalvular leakage of the aortic 
valve prosthesis n one case. The aortic valve prosthesis n 
the other patient appeared competent, but it had to be 
replaced because massive enlargement of the sinus of 
Valsalva precluded secure anchoring of an ascending 
aortic graft except as a composite graft. In all three 
patients of this subgroup, composit e graft replacement of
the aortic valve and ascending aorta was initially per- 
formed. Meanwhile, the systemic temperature was further 
lowered to 20 ° C. At this rectal temperature, a second 
period of circulatory arrest was induced to enable explo- 
ration of the aortic arch and subsequent distal reconstruc- 
tion if necessary. After implantation of the distal aortic 
anastomosis, cardiopulmonary bypass was reinstituted. 
During rewarming , the graft-to-graft anastomosis was 
